The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients.
Abstract
Background We undertook a randomised controlled trial to assess the efficacy and tolerability of orlistat, a gastrointestinal lipase inhibitor, in promoting weight loss and preventing weight regain in obese patients over a 2-year period. Methods 743 patients (body-mass index 28-47 kg/m2), recruited at 15 European centres, entered a 4-week, single-blind, placebo lead-in period on a slightly hypocaloric diet (600 kcal/day deficit). 688 patients who completed the lead-in were assigned double-blind treatment with orlistat 120 mg (three times a day) or placebo for 1 year in conjunction with the hypocaloric diet. In a second 52-week double-blind period patients were reassigned orlistat or placebo with a weight maintenance (eucaloric) diet. Findings From the start of lead-in to the end of year 1, the orlistat group lost, on average, more bodyweight than the placebo group (10.2% [10.3 kg] vs 6.1% [6.1 kg]; LSM difference 3.9 kg [p Interpretation Orlistat taken with an appropriate diet promotes clinically significant weight loss and reduces weight regain in obese patients over a 2-year period. The use of orlistat beyond 2 years needs careful monitoring with respect to efficacy and adverse events.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Weight regain has previously been observed following withdrawal of obesity pharmacotherapies, including orlistat and lorcaserin—and also semaglutide, as shown in STEP 4—despite continued lifestyle intervention.”
From Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension (2022) · cites this paper as [14]
In the citing paper
“By contrast, the STEP 4 study did not show a clear slowing of weight regain towards the end of its 48‐week observation period following semaglutide withdrawal.”
From Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension (2022) · cites this paper as [14]
In the citing paper
“Long‐term obesity pharmacotherapy may be required for weight maintenance, as cessation of pharmacological treatment is frequently followed by weight regain, even with continued lifestyle intervention. 13 , 14 , 15”
From Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension (2022) · cites this paper as [14]
In the citing paper
“There is also evidence that antiobesity medications, including long-acting glucagon-like peptide-1 (GLP-1) receptor agonists, naltrexone/bupropion, phentermine/topiramate, and orlistat, may help maintenance of achieved weight reduction.5,7,8,9,10,11,12”
From Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial (2024) · cites this paper as [11]
In the citing paper
“In the STEP 1 extension, weight regain was comparatively rapid following semaglutide withdrawal compared with that seen in other obesity pharmacotherapy withdrawal trials, including after semaglutide withdrawal in STEP 4.”
From Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension (2022) · cites this paper as [14]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kuczmarski, R. J. (1994) · JAMA · doi:10.1001/jama.272.3.205 · Cited by 2,362
Beneficial health effects of modest weight loss.
Dj, G. (1992) · PubMed · Cited by 1,263
Dietary fat and obesity: evidence from epidemiology.
Lissner, L., & Heitmann, B. L. (1995) · PubMed · Cited by 430
INTERNATIONAL TRIAL OF LONG-TERM DEXFENFLURAMINE IN OBESITY
Guy-Grand, B., Crepaldi, G., Vre, P., Apfelbaum, M., Gries, A., & Turner, P. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91499-2 · Cited by 309
Zhi, J., Melia, A. T., Guerciolini, R., Chung, J., Kinberg, J., Hauptman, J. B., & Patel, I. H. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.104 · Cited by 278
The role of dietary fat in obesity.
Golay, A., & Bobbioni, E. (1997) · PubMed · Cited by 236
Self-citationOrlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study.
Drent, M. L., Larsson, I., William-Olsson, T., QUAADE, F., Czubayko, F., von Bergmann, K., Strobel, W. M., Sjöström, L., & van der Veen, E. A. (1995) · PubMed · Cited by 208
Self-citationHuman Energy Requirements: A Manual for Planners and Nutritionists
James, W. P. T., & Schofield-Georgeson, E. (1990) · Cited by 185
Hauptman, J., Jeunet, F., & Hartmann, D. (1992) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/55.1.309s · Cited by 182
Siöström, C. D., Lissner, L., & Siostrom, L. (1997) · Obesity Research · doi:10.1002/j.1550-8528.1997.tb00572.x · Cited by 179
Research works printed but not linked: 1
- SIGN. Obesity in Scotland: integrating prevention with weight management. A National Clinical Guideline recommended for use in Scotland by the Scottish Intercollegiate Guidelines Network. Pilot edition, November, 1996.
Cited by
Poirier, P., Giles, T. D., Bray, G. A., Hong, Y., Stern, J. S., Pi-Sunyer, F. X., & Eckel, R. H. (2006) · Circulation · doi:10.1161/circulationaha.106.171016 · Cited by 3,165
Plasma Ghrelin Levels after Diet-Induced Weight Loss or Gastric Bypass Surgery
Cummings, D. E., Weigle, D. S., Frayo, R. S., Breen, P. A., Ma, M. K., Dellinger, E. P., & Purnell, J. Q. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012908 · Cited by 2,241
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Bariatric Surgery and Long-term Cardiovascular Events
Sjöström, L., Peltonen, M., Jacobson, P., Sjöström, C. D., Karason, K., Wedel, H., Ahlin, S., Anveden, Å., Bengtsson, C., Bergmark, G., et al. (2012) · JAMA · doi:10.1001/jama.2011.1914 · Cited by 1,656
Self-citation
Metadata
- Authors
- Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Helsinki University Hospital (FI)
- Copenhagen University Hospital (DK)
- University Hospital of Geneva (CH)
- Corresponding author
- Sjöström, Lars
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 1998-07
- Volume
- 352
- Issue
- 9123
- Pages
- 167-172
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2134860420
- Cited by
- 1,237
- References
- 22
- Citations by year
- 2026: 41 · 2025: 44 · 2024: 47 · 2023: 37 · 2022: 28 · 2021: 28 · 2020: 23 · 2019: 18 · 2018: 24 · 2017: 24 · 2016: 28 · 2015: 31 · 2014: 29 · 2013: 32 · 2012: 26
- FWCI
- 43.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- orlistat, obesity, weight loss, weight regain prevention, lipase inhibitors, hypocaloric diet, weight-maintenance diet, cholesterol, insulin, glucose, gastrointestinal adverse effects, long-term efficacy
- MeSH terms
- Orlistat, Adult, Blood Pressure, Energy Intake, Diet, Reducing, Double-Blind Method, Enzyme Inhibitors, Female, Follow-Up Studies, Humans, Lactones, Lipase, Lipids, Male, Middle Aged, Obesity, Risk Factors, Time Factors, Weight Loss, Body Mass Index, Single-Blind Method, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. https://app.cochat.ai/papers/10.1016/s0140-6736(97)11509-4
- The paper
- Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998). Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. The Lancet. https://doi.org/10.1016/s0140-6736(97)11509-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.